Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Breast Cancer Clinical Trial

Official title:

A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01466270
• Other study ID #: IRB00019792-1
• Secondary ID: U10CA081851REBAC
• Status: Completed
• Phase: Phase 2
• Start date: July 2012
• Est. completion date: October 1, 2013

Study information

• Verified date: September 2021
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Donepezil hydrochloride may help lessen cognitive dysfunction caused by chemotherapy.

PURPOSE: This phase II trial is studying donepezil hydrochloride in treating cognitive dysfunction after chemotherapy in female breast cancer survivors.

Description:

OBJECTIVES:

Primary

• Determine the feasibility of conducting a randomized placebo-controlled clinical trial for cognitive symptoms in female breast cancer survivors.

Secondary

• Estimate the variability of the clinical outcomes (FACT-Cognition Perceived Cognitive Impairment subscale, neurocognitive battery, FACIT-Fatigue, FACT Cog Total Score, PROMIS Fatigue, Epworth Sleepiness Scale, Beck Depression Inventory, Beck Anxiety Inventory, and RAND Short Form-36).

• Estimate the within patient correlation over time of the clinical outcomes.

• Obtain preliminary estimates of the effect of donepezil on the primary and secondary outcome variables.

• Correlate the reports of fatigue, sleep disturbance, and mood with measures of cognitive symptoms and neurocognitive test performance.

• Document the severity of cognitive symptoms and functional impairment in female breast cancer survivors who enroll on this pilot study.

• Correlate cognitive symptoms with cognitive test performance.

• Document the toxicities associated with donepezil hydrochloride use.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to menopausal status (pre- vs peri-/post-menopausal) and time since end of chemotherapy (12-36 months vs 36.01-60 months).

Arm I: Patients receive donepezil hydrochloride orally (PO) once daily (QD).

Arm II: Patients receive placebo PO QD.

In both arms treatment continues for 24 weeks.

Patients complete the entire battery of neurocognitive tests and questionnaires (FACT-Cognition Perceived Cognitive Impairment subscale, neurocognitive battery, FACIT-Fatigue, FACT Cog Total Score, PROMIS Fatigue, Epworth Sleepiness Scale, Beck Depression Inventory, Beck Anxiety Inventory, and RAND Short Form-36) at baseline (pre-treatment), 24 weeks (end of medication), and 36 weeks (end of wash-out).

After completion of therapy, patients are followed at 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: October 1, 2013
• Est. primary completion date: October 1, 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

• Adults >18 years old.

• Female with history of invasive breast cancer

• Must have completed adjuvant chemotherapy between 1 and 5 years prior to registration

• Received at least 4 cycles of cytotoxic chemotherapy

• Documentation of prior chemotherapy

• Patients receiving ongoing hormonal therapy for breast cancer must be on the same hormonal agent for at least 3 months prior to study registration and continue for the duration of the study (9 months)

• Karnofsky Performance Status must be > 60 or ECOG 0-2.

• Use of psychotropic medications (anti-depressants, anxiolytics, sleeping aids, narcotics) is permitted. Patient will be asked to list any that have been taken within the last 3 days on the recent medication sheet.

• Patients must be able to give informed consent to participate in the study, including signing the consent form.

• Self-reported cognitive disruption (FACT-Cog Version 3 Perceived Cognitive Impairments sub-score of < 63)

• Negative serum pregnancy test within 10 days prior to registration for women of child-bearing potential.

EXCLUSION CRITERIA:

• Evidence or suspected recurrent or metastatic disease

• History of dementia, Alzheimer's disease, multi-infarct dementia or CVA (history of transient ischemic attack (TIA is allowed)

• Current use of donepezil, galantamine, rivastigmine, tacrine, memantine, methylphenidate, dextroamphetamine, or any other specific cognition enhancing drugs.are not allowed. For patients who have used these medications they must not have used them within 4 weeks prior to registration.

Patients may not currently be taking Ketoconazole or Quinidine

• Hypersensitivity to donepezil.

• Use of investigational medications within the last 30 days.

• Prior brain metastasis

• Traumatic brain injury, multiple sclerosis or recent myocardial infarction

• History of schizophrenia, psychosis or substance abuse

• Untreated current severe depression. (Currently treated depression is permitted if treatment is stable.)

• Acute severe fatigue, chronic fatigue syndrome or fibromyalgia.

• History of hepatic or renal dysfunction or disease

• Pregnant women are excluded from this study. The effects of donepezil on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because donepezil is known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.

• It is unknown whether donepezil is excreted in breast milk, for this reason women who are currently breast-feeding are not eligible for this study.

Related Conditions & MeSH terms

• Anxiety Disorder
• Anxiety Disorders
• Breast Cancer
• Breast Neoplasms
• Cognition Disorders
• Cognitive Dysfunction
• Depression
• Disease
• Fatigue
• Parasomnias
• Sleep Disorders
• Sleep Wake Disorders

Intervention

Drug:
• donepezil hydrochloride
Given PO
• Placebo
Given PO

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention	Retention is the percentage of participants who stay in the study for 24 weeks.	24 Weeks
Primary	Compliance	Compliance is the percentage of pills taken while on study (based on returned diaries)	24 weeks
Secondary	HVLT-IR	Hopkins verbal learning test - immediate recall is the number of words (of 12) than can be remembers during three tries. The total score ranges from 0 to 36. Higher is better.	24 weeks
Secondary	Fatigue	Fatigue is quantified by the FACIT-Fatigue scale. It consists of 13 questions answered on a 0 to 4 point scale. The fatigue score is the sum of the responses (some reverse scored) so that higher values represent less fatigue.	24 weeks